Ex-Trulieve Employees Speak Out Following Colleague’s Death Tied To Cannabis Dust Inhalation
Following the recently released report offering more details into what happened on Jan.
TILT Debuts Social Impact Driven Brand Black Buddha Cannabis In Massachusetts, This State Is Next
TILT Holdings Inc. (NEO: TILT) (OTCQX: TLLTF) announced on Thursday the Massachusetts launch of Black Buddha Cannabis, a Black and woman-owned and led environmentally conscious, social impact-driven cannabis wellness brand.
This Legal Psychoactive Mushroom Reduces Stress And Pain And Encourages Longevity, Expert Says
This article was originally published in December 2021.
Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood.
Ayr Wellness Rolls Out Concentrates Brand HAZE With Rapid Onset Products To Florida
Vertically-integrated cannabis company Ayr Wellness Inc. (CSE:AYR.A) (OTCQX: AYRWF) is rolling out its premium live resin concentrates and vapes brand HAZE in Florida.
Mushroom Tea For Use In Psychedelic Research Developed By Numinus Wellness
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based psychedeli
MJ Holdings To Unveil First Cannabis Crypto ‘Fractional Farming Token’ At Las Vegas’ Web3Expo
On October 5, MJ Holdings Inc. (OTCQB: MJNE), a publicly traded cannabis company, announced it will be presenting “the details of MJ Holdings’ groundbreaking Digital Asset Tokenization Project" during the
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.
Curaleaf Finalizes EBITDA Accretive Tryke Acquisition, Now Has 29 Growing Sites & 144 Dispensaries
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) completed its
EXCLUSIVE: atai’s Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).
High Times, Elegance, Emerald Health Pharmaceuticals Among 8 Cannabis Co. Involved in Promotion Scheme, Says SEC
On September 30, the Securities and Exchange Commission (SEC) announced that it had charged eight cannabis stocks, in a stock promotion scheme that included Emerald Health Pharmaceuticals, Elegance Brands Inc.